Similar articles

• The roles of the pharmaceutical industry and drug development in dermatology and dermatologic health care.

  Altman DJ. Altman DJ. Dermatol Clin. 2000 Apr;18(2):287-96. doi: 10.1016/s0733-8635(05)70174-1. Dermatol Clin. 2000. PMID: 10791155 Review.
• Commentary: unapproved uses, dosages, or indications in dermatology: a physician's reference.

  Wolf R. Wolf R. Clin Dermatol. 2002 Sep-Oct;20(5):465-6. doi: 10.1016/s0738-081x(02)00275-4. Clin Dermatol. 2002. PMID: 12435515 No abstract available.
• Dissecting drug pricing: Supply chain, market, and nonmarket trends impacting clinical dermatology.

  Nguyen HP, Go JA, Barbieri JS, Stough D, Stoff BK, Forman HP, Bolognia JL, Albrecht J; Group for Research of Policy Dynamics in Dermatology. Nguyen HP, et al. J Am Acad Dermatol. 2020 Aug;83(2):691-699. doi: 10.1016/j.jaad.2020.04.063. Epub 2020 Apr 21. J Am Acad Dermatol. 2020. PMID: 32330637 No abstract available.
• Sources of bias in the economic analysis of new drugs.

  Rakatansky H. Rakatansky H. JAMA. 2000 Mar 15;283(11):1424. JAMA. 2000. PMID: 10732928 No abstract available.
• Notification vs approval.

  Novack GD. Novack GD. Ocul Surf. 2007 Jul;5(3):255-8. doi: 10.1016/s1542-0124(12)70616-x. Ocul Surf. 2007. PMID: 17660899 Review. No abstract available.